Systemic capillary leak syndrome after granulocyte colony-stimulating factor (G-CSF)

Hematol J. 2003;4(1):54-6. doi: 10.1038/sj.thj.6200211.

Abstract

Capillary leak syndrome (CLS) commonly occurs in the intensive care setting. CLS is seen in conditions such as septic shock or may result from conditions such as multitrauma and pancreatitis, which result in the systemic inflammatory response syndrome (SIRS). We present two cases in which both patients suffered with CLS, which we believe was caused following administration of granulocyte colony-stimulating factor, to our knowledge not described in the intensive care patient previously. We discuss how these patients management differs from other intensive care unit patients with CLS and how it is important to diagnose this condition early in haematological oncology cases.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Capillary Leak Syndrome / chemically induced*
  • Capillary Leak Syndrome / drug therapy
  • Capillary Leak Syndrome / physiopathology
  • Combined Modality Therapy
  • Critical Care
  • Cyclophosphamide / therapeutic use
  • Dexamethasone / administration & dosage
  • Doxorubicin / administration & dosage
  • Dyspnea / etiology
  • Edema / etiology
  • Edema / physiopathology
  • Fasciitis, Necrotizing / etiology
  • Fatal Outcome
  • Granulocyte Colony-Stimulating Factor / adverse effects*
  • Granulocyte Colony-Stimulating Factor / therapeutic use
  • Hematopoietic Stem Cell Mobilization / adverse effects*
  • Humans
  • Hydroxyurea / administration & dosage
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy
  • Male
  • Methylprednisolone / therapeutic use
  • Middle Aged
  • Models, Biological
  • Multiple Myeloma / complications*
  • Multiple Myeloma / drug therapy
  • Multiple Myeloma / therapy
  • Peripheral Blood Stem Cell Transplantation
  • Thalidomide / therapeutic use
  • Vasculitis, Leukocytoclastic, Cutaneous / chemically induced
  • Vincristine / administration & dosage

Substances

  • Granulocyte Colony-Stimulating Factor
  • Thalidomide
  • Vincristine
  • Dexamethasone
  • Doxorubicin
  • Cyclophosphamide
  • Methylprednisolone
  • Hydroxyurea

Supplementary concepts

  • VAD protocol